iRhythm Holdings, Inc. (IRTC) Stock Analysis
Recovery setup
Healthcare · Medical Devices
Wait for pullback to $117.74. Below 200-day MA (death cross); also weak momentum — blocks BUY_NOW at $125.16. Engine's entry $117.74 (Ma50 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: iRhythm Services; Leverage penalty (D/E 4.8): -1.5.
iRhythm Holdings provides ambulatory cardiac monitoring services using its Zio wearable biosensor and proprietary cloud-based analytics for detecting arrhythmias. Revenue comes from billing Medicare (~24% in 2025) and commercial payors for long-term continuous monitoring and... Read more
Wait for pullback to $117.74. Below 200-day MA (death cross); also weak momentum — blocks BUY_NOW at $125.16. Engine's entry $117.74 (Ma50 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: iRhythm Services; Leverage penalty (D/E 4.8): -1.5. Chart setup: Death cross but MACD improving, RSI 63. Earnings in 0 days. Wait until post-earnings. Score 5.6/10, moderate confidence.
Passes 5/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on death cross (50MA < 200MA) and earnings proximity 0d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMCustomerMedicare program24%10-K Item 1A: 'During the year ended December 31, 2025, we received approximately 24% of our total revenue from the Medicare program through CMS.'
- HIGHProductiRhythm Services10-K Item 1A: 'Our current revenue is dependent on orders for our iRhythm Services ... account for substantially all our revenue for the foreseeable future.'
Material Events(8-K, last 90d)
- 2026-04-01Item 4.01HIGHPricewaterhouseCoopers LLP dismissed as independent registered public accounting firm on March 30, 2026. No disagreements or reportable events cited. Successor auditor not named in this filing.SEC filing →
- 2026-03-12Item 5.02LOWBoard appointed Jason Patten as director and Audit Committee member effective March 12, 2026. Term expires at 2026 Annual Meeting. Routine board appointment; no departure.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $117.74. Below 200-day MA (death cross); also weak momentum — blocks BUY_NOW at $125.16. Engine's entry $117.74 (Ma50 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: iRhythm Services; Leverage penalty (D/E 4.8): -1.5. Chart setup: Death cross but MACD improving, RSI 63. Earnings in 0 days. Wait until post-earnings. Target $169.65 (+35.5%), stop $107.28 (−16.7%), Setup A.R:R 5.3:1. Score 5.6/10, moderate confidence.
Take-profit target: $169.65 (+37.2% upside). Target $169.65 (+35.5%), stop $107.28 (−16.7%), Setup A.R:R 5.3:1. Stop-loss: $107.28.
Concentration risk — Product: iRhythm Services; Leverage penalty (D/E 4.8): -1.5.
iRhythm Holdings, Inc. trades at a P/E of N/A (forward 144.4). TrendMatrix value score: 6.2/10. Verdict: Buy (Wait for Entry).
21 analysts cover IRTC with a consensus score of 4.3/5. Average price target: $195.
What does iRhythm Holdings, Inc. do?iRhythm Holdings provides ambulatory cardiac monitoring services using its Zio wearable biosensor and proprietary...
iRhythm Holdings provides ambulatory cardiac monitoring services using its Zio wearable biosensor and proprietary cloud-based analytics for detecting arrhythmias. Revenue comes from billing Medicare (~24% in 2025) and commercial payors for long-term continuous monitoring and mobile cardiac telemetry services.